Retatrutide vs tirzepatide vs semaglutide: mechanisms and evidence
Compare receptor targets, regulatory context and the studies that can—and cannot—support a fair comparison of these three molecules.
In this article
Receptor targets and regulatory context
| Molecule | Receptor targets | Regulatory context in the sources reviewed |
|---|---|---|
| Semaglutide | GLP-1 | Wegovy has an EMA medicine record; authorization applies to the specified product and use. |
| Tirzepatide | GIP and GLP-1 | Mounjaro has an EMA medicine record; authorization applies to the specified product and use. |
| Retatrutide | GIP, GLP-1 and glucagon | Investigational; FDA says it is not an ingredient in an FDA-approved drug. |
A molecule name, a brand name and a research catalogue entry are different identifiers. A regulator’s decision about one finished medicine cannot be transferred to every powder, blend or alternative formulation using the same molecule name. Keep the exact product and jurisdiction attached to every approval statement.
Which comparison has direct clinical evidence?
SURMOUNT-5 directly compared tirzepatide with semaglutide in 751 adults with obesity but without type 2 diabetes. The randomized, open-label study reported mean weight changes at 72 weeks of −20.2% and −13.7%, respectively. Gastrointestinal events were the most common adverse events in both groups. Retatrutide was not included in that trial. [4]
That is evidence for the comparison actually tested, with its selected participants, regimens and follow-up. It is not evidence that the same difference will occur in every population or that retatrutide would occupy a particular position in that study. Open-label means participants and investigators knew the assigned treatment; it is one design feature to consider when interpreting a trial.
Why separate trial headlines cannot produce a reliable winner
A common comparison places the largest percentage from each molecule’s studies side by side. That display looks precise while leaving several questions unanswered. Were participants living with diabetes? Did the studies last the same length of time? Were treatment discontinuations handled the same way? Were the comparator and primary endpoint alike?
| Check | Why it changes interpretation |
|---|---|
| Study population | Different eligibility criteria limit how broadly a result can be applied. |
| Comparator and randomization | A direct randomized comparison addresses a different question from comparisons across separate placebo-controlled trials. |
| Duration | A result at one time point is not interchangeable with a result at another. |
| Analysis and missing outcomes | The result depends partly on what happens to participants who stop treatment or have missing measurements. |
| Safety and burden | A single efficacy average does not summarize adverse events, discontinuation or the overall treatment experience. |
What approval does—and does not—tell you
The EMA records cited here concern specific authorized medicines. The US FDA statement about retatrutide concerns a different molecule and a different jurisdiction. Combining those sources into a claim that all three are interchangeable would erase the distinctions the sources actually document. [1][2][5]
This comparison is educational. A treatment decision requires the current local label and individual clinical context. It cannot be made from a receptor diagram, a research catalogue price or a table of results from unrelated trials.
Common comparison questions
Is retatrutide a form of tirzepatide? No. They are distinct molecules with different receptor profiles. Similar research topics do not make their identities interchangeable. [3][2]
Does this article establish which is best? It explains one direct comparison and the limits of broader comparisons. “Best” requires a specified outcome, population and time horizon, as well as an assessment of harms. The evidence should determine the claim rather than the other way around.
Primary sources
Sources checked Sep 17, 2026. This is an editorial evidence summary, not a systematic review or individualized medical advice. PeptideTech operates an affiliate directory; these citations are primary research and regulatory sources, not vendor endorsements.
- Wegovy: European public assessment reportEU regulator · Checked Sep 17, 2026
- Mounjaro: European public assessment reportEU regulator · Checked Sep 17, 2026
- Retatrutide for obesity: randomized phase 2 trial (NEJM, 2023)Peer-reviewed clinical trial · Checked Sep 17, 2026
- Tirzepatide compared with semaglutide for obesity (NEJM, 2025)Peer-reviewed head-to-head trial · Checked Sep 17, 2026
- FDA concerns with unapproved GLP-1 drugs used for weight lossUS regulator · Checked Sep 17, 2026